RSS

abiraterone

According to new research from the US, a side-effect of a common prostate cancer drug can, in some men with advanced disease who have a specific genetic variant, actually fuel cancer cells. Read more

News

Data has been presented by AstraZeneca and Merck demonstrating clinical improvement in median radiologic progression-free survival (rPFS) with Lynparza (olaparib) in combination with abiraterone compared to abiraterone monotherapy, a standard of care Read more

News

Due to a price drop, the National Institute for Health and Care Excellence (NICE) has agreed that Janssen’s prostate cancer drug, abiraterone is now affordable, going back on its previous decision Read more

News